Juan Madoz-Gúrpide

13PUBLICATIONS
27CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Feb 26, 2025
Adaptive Proteomic Changes in Protein Metabolism and Mitochondrial Alterations Associated with Resistance to Trastuzumab and Pertuzumab Therapy in HER2-Positive Breast Cancer.

Juan Madoz-Gúrpide, Juana Serrano-López, Marta Sanz-Álvarez

|Jan 11, 2024
Generation and Characterization of Trastuzumab/Pertuzumab-Resistant HER2-Positive Breast Cancer Cell Lines.

Marta Sanz-Álvarez, Melani Luque, Miriam Morales-Gallego

|May 13, 2023
Deregulation of the miR-19b/PPP2R5E Signaling Axis Shows High Functional Impact in Colorectal Cancer Cells.

Andrea Santos, Ion Cristóbal, Cristina Caramés

|Apr 13, 2023
miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer.

Paula Cabello, Sandra Torres-Ruiz, Anna Adam-Artigues

|Feb 25, 2023
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer.

Sandra Torres-Ruiz, Eduardo Tormo, Iris Garrido-Cano

|Dec 23, 2022
Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer.

Melani Luque, Marta Sanz-Álvarez, Miriam Morales-Gallego

Pageof 3